8-K: Achieve Life Sciences Q2 2025: NDA Filed, $49.3M Raised

Achieve Life Sciences announced its second quarter 2025 financial results, highlighted by the submission of its New Drug Application for cytisinicline to the FDA and a successful $49.3 million public offering.

Summary

• Submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for cytisinicline as a treatment for nicotine dependence for smoking cessation in adults in June 2025.
• Announced a partnership with Omnicom in June 2025 to co-develop and execute a fully integrated launch strategy for cytisinicline, aiming to reduce commercial buildout costs and accelerate execution.
• Raised $49.3 million in gross proceeds from an underwritten public offering in June and July 2025, providing funding runway into the second half of 2026.
• Met FDA long-term safety requirements for the ORCA-OL trial, with over 300 participants completing at least six months and over 100 completing one year of cumulative cytisinicline treatment.
• Published Phase 3 ORCA-3 trial results in the Journal of American Medical Association (JAMA) Internal Medicine, reinforcing cytisinicline's efficacy and tolerability.
• Reported cash, cash equivalents, and marketable securities of $55.4 million as of June 30, 2025.
• Total operating expenses for Q2 2025 were $12.6 million, leading to a net loss of $12.7 million.

Sentiment

Score: 8

Explanation: The company achieved major milestones including NDA submission and significant capital raise, extending its financial runway. Positive clinical data publication and a strategic commercial partnership further strengthen its position. While operating expenses and net loss increased, this is expected for a late-stage biotech nearing commercialization. The primary remaining hurdle is FDA approval.

Positives

• Successful submission of the New Drug Application (NDA) for cytisinicline to the FDA in June 2025, a major milestone following a decade of research.
• Secured $49.3 million in gross proceeds from a public offering, extending the funding runway into the second half of 2026.
• Established a strategic partnership with Omnicom for a cost-efficient, streamlined, and data-driven commercial launch strategy for cytisinicline, leveraging AI-enabled platforms.
• Met FDA long-term safety requirements for cytisinicline in the ORCA-OL trial, with over 300 participants completing at least six months and over 100 completing one year of cumulative treatment.
• Publication of positive Phase 3 ORCA-3 trial results in JAMA Internal Medicine, consistent with earlier ORCA-2 trial findings, supporting cytisinicline's efficacy and tolerability.
• Cytisinicline has been granted Breakthrough Therapy designation by the FDA for vaping cessation, addressing a critical unmet need.
• Cash, cash equivalents, and marketable securities increased to $55.4 million as of June 30, 2025, from $34.36 million at December 31, 2024.

Negatives

• Total operating expenses increased to $12.6 million for Q2 2025, up from $8.4 million for Q2 2024.
• Net loss increased to $12.7 million for Q2 2025, compared to $8.5 million for Q2 2024.
• Net loss per share increased to $0.37 for Q2 2025, compared to $0.25 for Q2 2024.

Risks

• Cytisinicline may not demonstrate the hypothesized or expected benefits.
• Achieve may not be able to obtain additional financing to fund the development and commercialization of cytisinicline.
• Cytisinicline may not receive regulatory approval in a timely manner or at all, or be successfully commercialized.
• New developments in the smoking and vaping cessation landscapes may require changes in business strategy or clinical development plans.
• Achieve's intellectual property may not be adequately protected.
• General business and economic conditions.
• Risks related to the impact of macroeconomic and geopolitical conditions, including fluctuating inflation, interest and tariff rates, volatility in the debt and equity markets, actual or perceived instability in the global banking system, global health crises and pandemics, and geopolitical conflict.

Future Outlook

Achieve Life Sciences expects the recently secured funding of $49.3 million to provide a financial runway into the second half of 2026. The company is committed to working closely with the FDA to advance cytisinicline as a potential treatment option for adults seeking to overcome nicotine dependence, with the goal of it becoming the first new pharmacotherapy option for nicotine dependence in nearly two decades, if approved. They are also building an AI-enabled launch platform with Omnicom to execute a high-impact commercial launch.

Management Comments

• "This quarter represents a significant step forward for Achieve. After years of focused dedication, we've reached the major milestone of submitting our NDA for cytisinicline, established an innovative commercialization partnership with Omnicom, and secured financing to advance our vision." Rick Stewart, CEO.
• "By combining our evidenced-based science with an agile, technology-driven commercialization strategy, cytisinicline, if approved, would be the first new pharmacotherapy option for nicotine dependence in nearly two decades." Rick Stewart, CEO.
• "Submitting the NDA on schedule is an important milestone that reflects the hard work and dedication of our team and partners." Dr. Cindy Jacobs, President and Chief Medical Officer.
• "Cytisinicline is supported by a comprehensive clinical data package, and we're committed to working closely with the FDA to advance this important potential treatment option for adults seeking to overcome nicotine dependence." Dr. Cindy Jacobs, President and Chief Medical Officer.

Industry Context

The announcement positions cytisinicline to address a critical unmet public health need in nicotine dependence, given that tobacco use is the leading cause of preventable death globally, responsible for nearly half a million deaths annually in the U.S. If approved, cytisinicline would be the first new pharmacotherapy option for nicotine dependence in nearly two decades, entering a market with limited existing treatments. The company also highlights the growing issue of e-cigarette use, with approximately 17 million adult users and 1.6 million middle and high school student users in the U.S., and notes that there are currently no FDA-approved treatments specifically for e-cigarette cessation, a gap cytisinicline aims to fill with its Breakthrough Therapy designation.

Comparison to Industry Standards

• Cytisinicline, if approved, would be the first new pharmacotherapy option for nicotine dependence in nearly two decades, indicating a significant innovation gap in the market that it aims to fill.
• The Phase 3 ORCA-2 and ORCA-3 trials demonstrated significantly higher quit rates with cytisinicline compared to placebo, with results published in the Journal of American Medical Association (JAMA) Internal Medicine, a highly respected peer-reviewed journal, lending strong scientific credibility to the findings.
• The company has met FDA long-term safety requirements for cytisinicline in the ORCA-OL trial, with over 300 participants receiving at least six months of cumulative treatment and over 100 receiving one year, which is crucial for regulatory approval and differentiates its safety profile for extended use.
• The strategic partnership with Omnicom for commercialization, leveraging seven specialized agencies and an AI-enabled launch platform, represents an agile, technology-driven approach designed to reduce traditional commercial buildout costs and accelerate execution, potentially setting a new standard for pharmaceutical launches in this therapeutic area.
• Cytisinicline has received Breakthrough Therapy designation from the FDA for vaping cessation, a status granted to drugs that may demonstrate substantial improvement over available therapy on a clinically significant endpoint, highlighting its potential to address a currently unaddressed market segment.

Stakeholder Impact

• Shareholders: The successful NDA submission and significant capital raise could increase confidence and potentially lead to future share price appreciation if cytisinicline is approved. However, increased operating expenses and net loss indicate continued burn, and the public offering resulted in share dilution.
• Patients (Adults seeking to quit smoking/vaping): If approved, cytisinicline offers a new, potentially highly effective treatment option for nicotine dependence, addressing a significant unmet medical need.
• Employees: Continued progress and funding secure the company's operations and employment for the foreseeable future.
• Regulatory Authorities (FDA): The comprehensive NDA submission and ongoing dialogue are crucial for advancing a new treatment option for public health.
• Omnicom: The partnership signifies a new revenue stream and strategic collaboration opportunity for Omnicom's specialized agencies.

Next Steps

• Work closely with the FDA to advance cytisinicline through the regulatory review process.
• Co-develop and execute a fully integrated, data-driven commercial launch strategy for cytisinicline with Omnicom.
• Continue development of cytisinicline for vaping cessation, following a successful end-of-Phase 2 meeting with the FDA for a future vaping indication.
• Host a conference call on August 7, 2025, at 8:30 AM EDT to discuss results.

Key Dates

Recommendation

The company has achieved critical milestones, including the NDA submission for cytisinicline, which positions it for potential market entry in a significant unmet medical need. The successful $49.3 million capital raise provides a substantial runway into H2 2026, mitigating immediate financing risks. The strategic partnership with Omnicom for commercialization indicates a well-thought-out launch strategy. While the company is pre-revenue and operating expenses have increased, this is expected for a late-stage pharmaceutical company. The potential for cytisinicline to be the first new pharmacotherapy in nearly two decades, coupled with its Breakthrough Therapy designation for vaping cessation, presents a compelling long-term growth opportunity, assuming FDA approval. The current stage represents a high-risk, high-reward investment, but the recent achievements significantly de-risk the regulatory and financial aspects, making it an attractive opportunity for investors with a higher risk tolerance.

Keywords

Cytisinicline, Smoking cessation, Nicotine dependence, Vaping cessation, FDA NDA submission, Pharmaceutical, Biotechnology, Clinical trials, ORCA-3, ORCA-OL, Public offering, Drug development, Specialty pharmaceutical